NCT03735511

Brief Summary

The study was designed to evaluate the efficacy and safety of apatinib in the treatment of patients with gastric carcinoma.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
270

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2018

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 7, 2018

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 8, 2018

Completed
12 days until next milestone

Study Start

First participant enrolled

November 20, 2018

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2020

Completed
Last Updated

April 27, 2020

Status Verified

April 1, 2020

Enrollment Period

1.7 years

First QC Date

November 7, 2018

Last Update Submit

April 23, 2020

Conditions

Gastric Carcinoma

Outcome Measures

Primary Outcomes (1)

  • Overall Survival

    Overall Survival

    2015-2018

Secondary Outcomes (3)

  • Objective Response Rate

    2015-2018

  • Disease Control Rate

    2015-2018

  • Progression-Free Survival

    2015-2018

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Chinese patients who were pathologically or cytologically diagnosed gastric carcinoma and treated by apatinib.

You may qualify if:

  • Pathologically or cytologically confirmed gastric or residual gastric or gastroesophageal junction carcinoma;
  • Patients received apatinib treatment at least once.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Henan Cancer Hospital

Zhengzhou, Henan, 450008, China

Location

MeSH Terms

Conditions

Stomach Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesStomach Diseases

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 7, 2018

First Posted

November 8, 2018

Study Start

November 20, 2018

Primary Completion

August 1, 2020

Study Completion

August 1, 2020

Last Updated

April 27, 2020

Record last verified: 2020-04

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)